Pain Management and Opioids: Balancing Risks and Benefits

REMS-banner-www

Overview

The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

  • From 1999 to 2016 more than 630,000 people died from drug overdoses.
  • 115 Americans die every day from an opioid overdose.
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018. 

How to Take a FREE Course

Review safe prescribing habits and examine the difference between opioid medications to help ensure patient safety and effective pain management.

Online Course

Check out the Online Course which is available 24/7 to accommodate busy schedules. 

Upcoming Courses

Check out ASAM's CME Events or CO*RE Partner Events to find upcoming live courses or webinars.

Over 6,500 learners have participated in the ER/LA opioid continuing education activities provided by ASAM. If you are interested in hosting a course for your organization, visit Host a Course.


Who Should Attend

The intended audience is all providers involved in the treatment of patients with pain including: pain specialists, primary care physicians, physician assistants, nurse practitioners, advanced practice nurses, dentists, addiction medicine physicians, psychiatrists and other physicians and clinicians.


Learning Objectives

The updated curriculum launched in May 2019 with these learning objectives:

  • Describe the pathophysiology of pain as it relates to the concepts of pain management.
  • Accurately assess patients in pain.
  • Develop a safe and effective pain treatment plan.
  • Identify evidence-based non-opioid options for the treatment of pain.
  • Identify the risks and benefits of opioid therapy.
  • Manage ongoing opioid therapy.
  • Recognize behaviors that may be associated with opioid use disorder.

*This course is not intended to advocate for the use of opioids in the treatment of chronic pain, but to ensure proper education about prescribing practices should a medical provider determine that opioids are the best course of treatment. 


Credits

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

ASAM designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASAM designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2.5 AMA PRA Category 1 Credits™.


Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 member-led healthcare organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US FDA Blueprint.